Newly Formed Position Reflects Direction for Exco InTouch
This morning, Exco InTouch
Tim Davis, CEO of Exco InTouch, told
“We are primarily perceived as a technology company,” said Davis. “But that’s not what we are all about. Technology is the medium by which we reach the patient—from recruitment, to retention all the way through the trial.” Specifically, Exco InTouch is aligned along those clinical process divisions; recruitment, retention and compliance, and ePRO. “There are common threads through these processes, and Judith will be bringing her experience with the patients’ experience into all these areas,” explained Davis.
Exco InTouch’s solutions and services are based around its mobile phone technology. For example, some solutions the company provides include using cell phones to reach potential patients by enabling two-way text messaging for compliance or questions during a trial. Mobile phones also provide patients with a secure Internet diary.
The Journey of the Patient
“The challenge of the industry is around this compartmentalization of the processes,” said Davis. “Rarely is recruitment bridged to retention. We see companies that want to get their recruitment done and, ‘then we’ll think about retention.’” But to Davis, it’s about engagement. “I think recruitment is the wrong word. It’s having the patient engagement throughout the process. If they lose the patient after enrollment because they aren’t thinking about retention, it’s like closing the barn door after the horses have bolted.”
And that is where Teall’s expertise will help sponsors and CROs, as well as Exco InTouch, begin to bring the patient experience to bear across all areas. “Hopefully, we can get the industry to that level,” said Davis.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025